Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · IEX Real-Time Price · USD
34.95
+0.90 (2.64%)
May 31, 2024, 4:00 PM EDT - Market closed
Spyre Therapeutics Revenue
Spyre Therapeutics had revenue of $688.00K in the twelve months ending March 31, 2024, down -40.94% year-over-year. In the year 2023, Spyre Therapeutics had annual revenue of $886.00K, a decrease of -61.96%.
Revenue (ttm)
$688.00K
Revenue Growth
-40.94%
P/S Ratio
2,046.37
Revenue / Employee
$22,933
Employees
30
Market Cap
1.41B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
Dec 31, 2021 | 18.74M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 3.89M | -1.32M | -25.30% |
Dec 31, 2017 | 5.21M | 577.00K | 12.47% |
Dec 31, 2016 | 4.63M | -1.46M | -23.94% |
Dec 31, 2015 | 6.09M | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.42B |
Pacira BioSciences | 681.75M |
ANI Pharmaceuticals | 517.46M |
Alphatec Holdings | 511.63M |
BioCryst Pharmaceuticals | 355.40M |
Kiniksa Pharmaceuticals | 301.77M |
Arcus Biosciences | 237.00M |
Establishment Labs Holdings | 155.79M |
SYRE News
- 3 days ago - Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference - PRNewsWire
- 17 days ago - Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors - PRNewsWire
- 23 days ago - Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 2 months ago - Spyre Therapeutics Announces $180 Million Private Placement - PRNewsWire
- 3 months ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference - PRNewsWire
- 4 months ago - Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation - PRNewsWire